HCA Healthcare, Inc. (HCA)
NYSE: HCA · Real-Time Price · USD
431.92
-13.85 (-3.11%)
At close: Apr 28, 2026, 4:00 PM EDT
434.90
+2.98 (0.69%)
After-hours: Apr 28, 2026, 7:59 PM EDT
HCA Healthcare Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for HCA Healthcare stock have an average target of 511.84, with a low estimate of 410 and a high estimate of 590. The average target predicts an increase of 18.50% from the current stock price of 431.92.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HCA Healthcare stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 | 7 | 6 |
| Buy | 7 | 7 | 6 | 6 | 6 | 7 |
| Hold | 9 | 7 | 7 | 7 | 7 | 6 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 20 | 20 | 21 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $561 → $500 | Strong Buy | Maintains | $561 → $500 | +15.76% | Apr 27, 2026 |
| Barclays | Barclays | Buy Maintains $551 → $496 | Buy | Maintains | $551 → $496 | +14.84% | Apr 27, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $593 → $534 | Buy | Maintains | $593 → $534 | +23.63% | Apr 27, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $481 → $436 | Hold | Maintains | $481 → $436 | +0.94% | Apr 27, 2026 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $560 → $530 | Buy | Maintains | $560 → $530 | +22.71% | Apr 27, 2026 |
Financial Forecast
Revenue This Year
79.46B
from 75.60B
Increased by 5.11%
Revenue Next Year
83.32B
from 79.46B
Increased by 4.86%
EPS This Year
30.66
from 28.33
Increased by 8.23%
EPS Next Year
33.68
from 30.66
Increased by 9.84%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 84.4B | 89.3B | ||||||
| Avg | 79.5B | 83.3B | ||||||
| Low | 75.5B | 79.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.7% | 12.4% | ||||||
| Avg | 5.1% | 4.9% | ||||||
| Low | -0.2% | -0.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 33.83 | 36.27 | ||||||
| Avg | 30.66 | 33.68 | ||||||
| Low | 28.52 | 31.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.4% | 18.3% | ||||||
| Avg | 8.2% | 9.8% | ||||||
| Low | 0.7% | 2.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.